WO2007002217A3 - Mutations and polymorphisms of bcl-2 - Google Patents

Mutations and polymorphisms of bcl-2 Download PDF

Info

Publication number
WO2007002217A3
WO2007002217A3 PCT/US2006/024177 US2006024177W WO2007002217A3 WO 2007002217 A3 WO2007002217 A3 WO 2007002217A3 US 2006024177 W US2006024177 W US 2006024177W WO 2007002217 A3 WO2007002217 A3 WO 2007002217A3
Authority
WO
WIPO (PCT)
Prior art keywords
bcl2
mutations
polymorphisms
mutant
various aspects
Prior art date
Application number
PCT/US2006/024177
Other languages
French (fr)
Other versions
WO2007002217A2 (en
Inventor
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Kenneth Wayne Culver, Jian Zhu, Stan Lilleberg filed Critical Novartis Ag
Publication of WO2007002217A2 publication Critical patent/WO2007002217A2/en
Publication of WO2007002217A3 publication Critical patent/WO2007002217A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the BCL2 gene. The invention provides new BCL2 mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the BCL2 mutations of the invention, expression vectors encoding the BCL2 mutant polypeptides of the invention and organisms that express the BCL2 mutant and polymorphic polynucleotides and/or BCL2 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the BCL2 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
PCT/US2006/024177 2005-06-22 2006-06-20 Mutations and polymorphisms of bcl-2 WO2007002217A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69299005P 2005-06-22 2005-06-22
US60/692,990 2005-06-22

Publications (2)

Publication Number Publication Date
WO2007002217A2 WO2007002217A2 (en) 2007-01-04
WO2007002217A3 true WO2007002217A3 (en) 2007-09-20

Family

ID=37595808

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/024177 WO2007002217A2 (en) 2005-06-22 2006-06-20 Mutations and polymorphisms of bcl-2

Country Status (1)

Country Link
WO (1) WO2007002217A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10106590B2 (en) 2013-03-15 2018-10-23 Dana-Farber Cancer Institute, Inc. BH4 stabilized peptides and uses thereof
US11466064B2 (en) 2016-08-26 2022-10-11 Dana-Farber Cancer Institute, Inc. Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002097094A1 (en) * 2001-05-30 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002097094A1 (en) * 2001-05-30 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KIRKIN V ET AL: "The role of Bcl-2 family members in tumorigenesis", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1644, no. 2-3, 1 March 2004 (2004-03-01), pages 229 - 249, XP004494139, ISSN: 0167-4889 *
OTTILIE S ET AL: "Structural and functional complementation of an inactive Bcl-2 mutant by Bax truncation.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 4 JUL 1997, vol. 272, no. 27, 4 July 1997 (1997-07-04), pages 16955 - 16961, XP002434496, ISSN: 0021-9258 *
PACKHAM G: "Mutation of BCL-2 Family Proteins in Cancer.", APOPTOSIS : AN INTERNATIONAL JOURNAL ON PROGRAMMED CELL DEATH MAR 1998, vol. 3, no. 2, March 1998 (1998-03-01), pages 75 - 82, XP009083710, ISSN: 1360-8185 *
PARK BYUNG LAE ET AL: "Identification of variants in cyclin D1 (CCND1) and B-cell CLL/lymphoma 2 (BCL2)", JOURNAL OF HUMAN GENETICS, vol. 49, no. 8, 2004, pages 449 - 454, XP002434497, ISSN: 1434-5161 *
SINICROPE FRANK A ET AL: "Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 DEC 2004, vol. 10, no. 24, 15 December 2004 (2004-12-15), pages 8284 - 8292, XP002434498, ISSN: 1078-0432 *
WATSON ALASTAIR J M ET AL: "Lessons from Genetically Engineered Animal Models VII. Apoptosis in intestinal epithelium: Lessons from transgenic and knockout mice", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 278, no. 1 part 1, January 2000 (2000-01-01), pages G1 - G5, XP009083729, ISSN: 0002-9513 *

Also Published As

Publication number Publication date
WO2007002217A2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
WO2007016532A3 (en) Mutations and polymorphisms of hdac4
WO2006130527A3 (en) Mutations and polymorphisms of fibroblast growth factor receptor 1
WO2009132058A3 (en) Levels of bcma protein expression on b cells and use in diagnostic methods
WO2005033652A3 (en) Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2002086448A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
HK1093674A1 (en) Anti-april monoclonal antibody and its use for the treatment of an immune related disease or cancer
WO2006105252A3 (en) Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
WO2004044557A3 (en) Non-invasive measurement of analytes
EP2287340A3 (en) Method for diagnosis and treatment of a mental disease
EP2293074A3 (en) Method for diagnosing neuro-degenerative disease
WO2006128042A3 (en) Methods of identifying mutations in nucleic acid
MX2009003562A (en) Elisa for vegf.
WO2009077864A3 (en) Compositions and methods of detecting tiabs
NZ596614A (en) Diagnosis and treatment of alzheimer's disease
WO2006110478A3 (en) Mutations and polymorphisms of epidermal growth factor receptor
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
WO2007022041A3 (en) Mutations and polymorphisms of hdac3
GB0516145D0 (en) In vitro diagnostic kit for identification of human papillomavirus in clinical samples
EP2644588A3 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
MX2007008984A (en) Cancer markers and detection methods.
ATE432997T1 (en) THERAPY MONITORING FOR TUMORS USING ACC133 MRNA
WO2005118403A3 (en) Methods for detecting gene expression in peripheral blood cells and uses thereof
WO2007030455A3 (en) Mutations and polymorphisms of hdac10
Kelada et al. Gender difference in the interaction of smoking and monoamine oxidase B intron 13 genotype in Parkinson’s disease

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06773707

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06773707

Country of ref document: EP

Kind code of ref document: A2